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Intracellular targeting of annexin 
A2 inhibits tumor cell adhesion, 
migration, and in vivo grafting
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Cytoskeletal-associated proteins play an active role in coordinating the adhesion and migration 
machinery in cancer progression. To identify functional protein networks and potential inhibitors, we 
screened an internalizing phage (iPhage) display library in tumor cells, and selected LGRFYAASG as 
a cytosol-targeting peptide. By affinity purification and mass spectrometry, intracellular annexin A2 
was identified as the corresponding binding protein. Consistently, annexin A2 and a cell-internalizing, 
penetratin-fused version of the selected peptide (LGRFYAASG-pen) co-localized and specifically 
accumulated in the cytoplasm at the cell edges and cell-cell contacts. Functionally, tumor cells 
incubated with LGRFYAASG-pen showed disruption of filamentous actin, focal adhesions and caveolae-
mediated membrane trafficking, resulting in impaired cell adhesion and migration in vitro. These effects 
were paralleled by a decrease in the phosphorylation of both focal adhesion kinase (Fak) and protein 
kinase B (Akt). Likewise, tumor cells pretreated with LGRFYAASG-pen exhibited an impaired capacity to 
colonize the lungs in vivo in several mouse models. Together, our findings demonstrate an unrecognized 
functional link between intracellular annexin A2 and tumor cell adhesion, migration and in vivo grafting. 
Moreover, this work uncovers a new peptide motif that binds to and inhibits intracellular annexin A2 as 
a candidate therapeutic lead for potential translation into clinical applications.
Cell adhesion and migration require dynamic remodeling of the cytoskeleton. This process results from 
the coordinated activity of several proteins, among which members of the annexin family of calcium- and 
phospholipid-binding proteins1, 2. Annexins are involved in a variety of processes including membrane organ-
ization, intracellular trafficking, and cytoskeleton remodeling in normal and diseased tissues3–5. In vertebrates, 
annexins are grouped into 12 subfamilies that share a basic structural core composed of four annexin repeats 
(eight in annexin A6) mediating reversible calcium-dependent binding to biological membranes, and a variable 
N-terminal domain responsible for protein-protein interactions4. In addition, annexins 1 and 2 include phos-
phorylation domains for different signal transducing kinases, as well as binding sites for the calcium-binding 
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proteins S100A10 and S100A11. Annexin A2 is anchored at the plasma membrane as a heterotetrameric complex 
with S100A106. This complex interacts with cytoskeleton components such as filamentous actin (F-actin) in the 
assembly of dynamic structures during phagocytosis, pinocytosis and cell migration3, 7.
Clinical studies have shown that annexin A2 is highly expressed in different tumor types, including gastric, 
colorectal, pancreatic, breast, and kidney cancers, high-grade gliomas, along with vascular tumors8–12. Preclinical 
studies have revealed a functional role for extracellular annexin A2 in the regulation of adhesion, migration, 
homing, and invasion of cancer cells13–16. Several annexin A2-interacting proteins, e.g. epithelial growth factor 
receptor (EGFR)17, migration and invasion enhancer 1 (MIEN1)16, galectin-315, and β1 integrin18, have been 
described to mediate tumor progression through phosphorylation and translocation of annexin A2 to the cell 
surface. Extracellular annexin A2, in association with S100A10, regulates the proteolytic activity of plasmin, lead-
ing to hydrolysis and remodeling of the extracellular matrix (ECM) and activation of matrix metalloproteases in 
tumor invasion19, 20. Although annexin A2 has been extensively studied as a component of supramolecular com-
plexes at the cell surface, it is also abundant as a cytosolic monomer. However, its role as an intracellular protein 
in cancer progression is not well understood.
We have recently designed and validated internalizing iPhage random peptide display libraries, an enabling 
platform based on viral particles that can be delivered intracellularly by exploiting the receptor-independent 
internalization of a penetratin (pen) moiety fused to the major capsid protein. This combinatorial approach 
allowed the identification and characterization of motifs targeting certain organelles and their molecular 
pathways within live cells21, 22. Here we report the discovery of an annexin A2 targeting motif, LGRFYAASG, 
identified by screening an iPhage library in KS1767, a human Kaposi’s sarcoma-derived cell line. A synthetic 
cell-penetrating version of this peptide (LGRFYAASG-pen) interacts with intracellular annexin A2 and disrupts 
F-actin and focal adhesions, thus impacting on tumor cell shape and impairing their attachment to the ECM. At 
the molecular level, tumor cells incubated with LGRFYAASG-pen show decreased phosphorylation of Fak and 
Akt, indicating a specific involvement of focal adhesion-associated annexin A2. The intracellular targeting of 
annexin A2 also reduces caveolae-related trafficking, supporting an effect on lipid raft stability and cell signaling. 
Finally, LGRFYAASG-pen inhibits tumor cell migration in vitro and reduces the formation of experimental lung 
colonies in vivo. Together, our results provide mechanistic insights into the association of intracellular annexin A2 
with the cytoskeletal machinery in tumor cells, and exploit its role as an intracellular target in cancer progression.
Results
The iPhage-displayed LGRFYAASG peptide serves as intracellular ligand for annexin A2. To 
identify cell-penetrating agents targeting intracellular proteins, we screened a random iPhage peptide library in 
cultured KS1767 Kaposi’s sarcoma cells. After overnight incubation, iPhage clones were collected from the cytosol 
fraction of whole cell lysates, recovered and amplified by E. coli infection, and purified for successive selection 
rounds. After five rounds of synchronous selection, the LGRFYAASG motif was specifically enriched and further 
investigated. By solid-phase (Merrifield) synthesis, a cell-internalizing version of the corresponding soluble pep-
tide was generated via C-terminal fusion to the pen motif. Affinity chromatography served to purify the intracel-
lular protein binding partner(s) for LGRFYAASG-pen in KS1767 cell lysates. Eluted fractions were immobilized 
in 96-well plates and phage binding assays revealed high concentrations of potential interactors in fractions 
F45–47 (Fig. 1a). Proteins with molecular weights of 33, 36 and 38 kDa were recovered from fraction F46 and 
analyzed by mass spectrometry, leading to the identification of three candidates: F-actin capping protein alpha-1 
subunit (CAPZA1), Lim SH3 protein 1 (LASP1), and annexin A2 (Table S1). A bioinformatic analysis suggested 
that CAPZA1, LASP1 and annexin A2 interact through a network of proteins, some of which are related to 
cytoskeleton dynamics, cell adhesion and migration in cancer, namely fibronectin23, α-actin24, and growth factor 
receptor-bound protein 2 (Grb2)25, 26 (Fig. 1b). We tested the interaction of the LGRFYAASG-displaying iPhage 
with each candidate recombinant protein, and observed specific binding to annexin A2, but not to either LASP1 
or CAPZA1 (Fig. 1c). Other proteins of the family (annexins A1, A4, and A5) showed background binding only 
(Fig. 1d). Binding of LGRFYAASG-iPhage to annexin A2 was inhibited in a concentration-dependent manner by 
the synthetic peptide LGRFYAASG-pen, indicating a specific saturable interaction (Fig. 1e). Alanine-scanning 
mutagenesis of the iPhage-displayed LGRFYAASG sequence identified the arginine (R3) and phenylalanine (F4) 
residues as critical for binding to annexin A2 (Fig. 1f). Together, our findings confirm LGRFYAASG-pen as a 
specific peptide ligand for annexin A2.
LGRFYAASG-pen disassembles focal adhesions, actin filaments and lipid microdomains. To 
gain mechanistic insight, we investigated the intracellular interaction between the targeting peptide and annexin 
A2 by confocal immunofluorescence (IF) microscopy. A biotin-conjugated version of either LGRFYAASG-pen 
or control peptides (pen only, unconjugated LGRFYAASG) was incubated for 2 h with cultured KS1767 cells, 
and successively visualized with avidin-fluorescein isothiocyanate (FITC). In these assays, a cytoplasmic 
co-localization of LGRFYAASG-pen and annexin A2 was observed in discontinuous cellular structures, par-
ticularly at the cell edges and at sites of cell-cell interaction (Fig. 2a, rightmost microphotograph). In contrast, 
neither avidin-FITC nor the unconjugated peptide accumulated within the cells. Detectable amounts of pen and 
LGRFYAASG-pen were visible in intracellular vesicles with the structure of lysosomes (Fig. 2a, green spots), 
suggesting that some excess peptide might have entered this degradation pathway. Cytoplasmic annexin A2 has 
been shown associated to the actin cytoskeleton27, 28, as well as to the acidic phospholipids present in specific 
membrane microdomains29, 30. The peculiar co-localization of LGRFYAASG-pen and annexin A2 (Fig. 2a) was 
somehow reminiscent of such cell compartments, and suggested that interfering with intracellular annexin A2 
might impact on their appearance, integrity and/or functionality. To test this working hypothesis, we first evalu-
ated the actin-based structures and membrane-cytoskeleton linkages. KS1767 cells were seeded on an admixture 
of fibronectin and vitronectin, and incubated overnight with LGRFYAASG-pen or control peptides. Staining 
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for actin and paxillin31 revealed disassembly of F-actin and disappearance of focal adhesions, respectively, in 
cells treated with the intracellular annexin A2-targeting peptide, but not with control peptides including the 
non-internalizing LGRFYAASG (Fig. 2b). A similar outcome was obtained with cells seeded on type I colla-
gen (Fig. 2c), demonstrating that this mechanism is independent of the ECM composition. In support of these 
findings, specific co-localization of annexin A2 and paxillin was detected in KS1767 cells under the same exper-
imental conditions (Fig. 2d). The unambiguous involvement of annexin A2 in the maintenance of cell structure 
Figure 1. The LGRFYAASG peptide motif is a specific intracellular ligand for annexin A2. (a) iPhage binding 
assays on protein fractions obtained by affinity chromatography. BSA was used as a negative protein control. 
TU values were normalized on binding of the insertless iPhage to annexin A2. (b) In silico analysis of potential 
interactions among the mass spectrometry-identified proteins in the canonical actin cytoskeleton pathway, 
as determined by the IPA protein network prediction software. ANXA2, annexin A2. (c) Binding of iPhage 
to GST-fused recombinant annexin A2, LASP1, and CAPZA1. GST and BSA served as protein controls. (d) 
Binding of LGRFYAASG-iPhage to recombinant annexin A1 (ANXA1), A2 (ANXA2), A4 (ANXA4), and A5 
(ANXA5). (e) Binding of LGRFYAASG-iPhage to annexin A2 in the presence of increasing concentrations of 
the synthetic peptide LGRFYAASG-pen. Unconjugated pen was used as a control, and binding in the absence 
of the inhibiting peptide was set at 100%. (f) Binding of alanine scanning variants of LGRFYAASG-iPhage. 
TU values were normalized on binding of an insertless iPhage, and bars represent mean values of triplicate 
experimental points ± standard error of the mean (SEM).
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integrity was further confirmed by silencing annexin A2 with specific lentiviral shRNA clones (Fig. S1a). KS1767 
cells with silenced expression of annexin A2 exhibited the same disruption of F-actin and focal adhesions 
observed upon LGRFYAASG-pen treatment (compare Fig. 2b,c with GFP-positive cells in Fig. S1b,c). At the 
molecular level, incubation of KS1767 cells with LGRFYAASG-pen resulted in a time-dependent decreased 
phosphorylation of the focal adhesion-associated kinases Fak32 (Tyr397) and Akt (Ser473), while no inhibitory 
effect was observed on mitogen-activated kinase Erk1/2 (p42/p44, Thr202/Tyr204) (Fig. 2e). We next investigated 
the effect of LGRFYAASG-pen on KS1767 cell membrane organization, in particular on phosphatidyl inositol 
4,5-bisphosphate-, cholesterol- and glycosphingolipid-rich microdomains defined as lipid rafts or caveolae33. 
Staining of caveolin-1 revealed disruption of caveolae in the presence of LGRFYAASG-pen (but not of control 
peptides), indicative of an impaired membrane trafficking (Fig. 2f). Together, these results show that the intracel-
lular annexin A2-targeting peptide inhibits annexin A2-driven modulation of actin cytoskeleton, focal adhesions 
and lipid microdomains, with repercussion on cell signaling.
Figure 2. LGRFYAASG-pen co-localizes with annexin A2 and disrupts actin filaments, focal adhesions and 
caveolin-rich microdomains. (a) Co-localization analysis: KS1767 cells grown overnight onto circular coverslips 
were incubated for 2 h at 37 °C with biotinylated LGRFYAASG-pen, or unconjugated LGRFYAASG (10 µM). 
Untreated cells were used as controls. IF staining of biotinylated peptides (avidin-FITC, green) and annexin A2 
(Cy3-conjugated secondary antibody, red) was analyzed with Fiji ImageJ. Co-localized pixels are visualized in 
white (arrows), and Manders’ overlap coefficients are reported in the graph (**P < 0.01; ***P < 0.001 versus 
LGRFYAASG-pen). (b,c) Disassembly of actin filaments: IF staining of paxillin (FITC-conjugated secondary 
antibody, green) and actin (rhodamine-phalloidin, red) in KS1767 cells grown onto (b) fibronectin/vitronectin- 
or (c) type I collagen-coated coverslips. (d) Localization of annexin A2 at the focal adhesions: KS1767 cells 
co-stained for paxillin (FITC-conjugated secondary antibody, green) and annexin A2 (Alexa 647-conjugated 
secondary antibody, red). An enlarged inset (white dotted line) is included for prompt visualization. (e) Western 
blot of Fak, Akt and Erk1/2 phosphorylation following KS1767 cell incubation with pen only or LGRFYAASG-
pen for the indicated periods of time. Total Fak, Akt, Erk1/2 were used as a reference, and actin served as 
loading control. (f) Disruption of caveolin-rich microdomains: KS1767 cells incubated with the peptides 
(30 µM) followed by IF staining of caveolin-1 (FITC-conjugated secondary antibody, green) and actin (red). In 
(b), (c), (d), (f), nuclei are visualized with DAPI (blue); in all micrographs: scale bar, 10 µm.
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LGRFYAASG-pen inhibits tumor cell adhesion and migration. To further validate the bio-
logical effect of LGRFYAASG-pen, we performed adhesion assays with KS1767 human Kaposi’s sar-
coma, KRIB human osteosarcoma, B16F10 murine melanoma and Lewis lung mouse carcinoma (LLC) 
cell lines on fibronectin- or vitronectin-coated wells. In preliminary assays, increasing concentrations 
of LGRFYAASG-pen progressively inhibited KS1767 cell attachment, whereas no detectable effect was 
observed with controls, including either pen alone or the non-internalizing LGRFYAASG peptide (Fig. S2a). 
A specific inhibition of cell adhesion by LGRFYAASG-pen was observed in the complete cell panel, and 
was independent of tumor type (sarcoma, melanoma or carcinoma), species origin (human or murine), and 
adhesive matrix (fibronectin or vitronectin) (Fig. 3), suggesting an overall impairment of the cytoskeleton. 
We next tested the same cell lines in transwell (Fig. 4a) and wound-healing (Fig. 4b) migration assays. In 
both cases, a specific inhibition was observed for all tumor cell lines in the presence of LGRFYAASG-pen 
compared to the controls. In the in vitro wound-healing assays, migration of LLC cells was inhibited at lower 
molar concentrations (3–10 μM), while KS1767, KRIB and B16F10 cells were inhibited at higher molar con-
centrations (100 μM) (Fig. 4b). Cells remained viable, and grew with an unaltered kinetics for up to 96 h at 
the highest concentrations of either LGRFYAASG-pen or control peptides, ruling out non-specific toxicity 
as a cause of the decreased adhesion (Fig. S2b). Together, these data show that LGRFYAASG-pen impairs 
tumor cell adhesion and migration, likely by inhibiting annexin A2-dependent membrane-cytoskeleton 
attachment and organization of actin-based structures.
Figure 3. LGRFYAASG-pen inhibits adhesion of tumor cells. Adhesion of KRIB, KS1767, B16F10 and LLC 
cells to fibronectin or vitronectin in the presence of LGRFYAASG-pen (30 µM). Unconjugated LGRFYAASG 
and pen served as negative controls (***P < 0.0001 versus control experimental points).
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LGRFYAASG-pen impairs experimental tumor engrafting in vivo. Having demonstrated that 
LGRFYAASG-pen alters the adhesion and migration of cancer cells in vitro, we asked whether it would also affect 
the onset of experimental tumors in vivo. For this purpose, we chose a well-characterized model of lung colo-
nization that provides an optimal short time-frame window for evaluating effects on tumor growth. The in vivo 
highly aggressive KRIB (Fig. 5a), B16F10 (Fig. 5b), or LLC (Fig. 5c) cells were incubated for 30 min with either 
LGRFYAASG-pen or control peptides prior to intravenous administration in mice. LGRFYAASG-pen-treated 
cells showed diminished colonization of the lungs, as evidenced by significantly fewer tumor foci compared 
to control-incubated cells. The lungs were pathologically evaluated by hematoxylin and eosin (H&E) stain-
ing, which confirmed that fewer and smaller microscopic foci developed from tumor cells pre-treated with 
LGRFYAASG-pen (Fig. S3). These findings demonstrate that presumably the cell-internalizing LGRFYAASG-pen 
peptide impairs lung colonization by tumor cells in preclinical models by interfering with annexin A2-mediated 
cell adhesion and/or migration.
Discussion
Here we identify and characterize the LGRFYAASG peptide as a targeting moiety that binds to intracellular 
annexin A2 and interferes with tumor cell adhesion and migration in vitro, resulting in impaired tumor grafting 
in vivo. Given the high expression of annexin A2 in many human tumors8–12, this discovery represents a promis-
ing step towards potential therapeutic intervention.
Figure 4. LGRFYAASG-pen inhibits tumor cell migration. (a) Transwell cell migration assays: 105 cells were 
applied to the upper chamber of transwell inserts in the presence of each peptide (100 µM for KS1767, KRIB, 
B16F10, 10 µM for LCC). After 24 h, migrated cells were fixed, stained in crystal violet and counted (5 fields/
well) under a light microscope (**P < 0.001; ***P < 0.0001 versus the control experimental points). (b) Wound-
healing cell motility assays performed with KS1767, KRIB, LLC and B16F10 cells. A wound was produced with a 
pipetman tip in confluent cell layers, followed by incubation with either medium only or the indicated peptides 
(3–30 μM for KS1767, 10–100 μM for KRIB and B16F10, 1–10 μM for LLC). The width of the wounds was 
imaged with a phase-contrast microscope, and is represented as percent of wound closure. Micrographs refer to 
the highest peptide concentrations. Scale bar, 100 µm. (**P < 0.001; ***P < 0.0001 versus control experimental 
points).
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Annexin A2 is a pleiotropic protein involved in a wide range of molecular and cellular processes that con-
verge on the regulation of cell shape, adhesion, and motility. The participation of extracellular annexin A2 has 
been widely described in cell migration18, 34–36. In particular, many studies suggest that annexin A2-mediated 
tumor cell invasiveness is attributable to the generation of extracellular plasmin through modulation of 
S100A10 enzyme activity. In our findings, we show that the intracellular pool of annexin A2 also plays an 
important role as a regulator of tumor cell adhesion, migration, and, potentially, secondary dissemination. 
Annexin A2 includes binding sites for calcium, actin and acidic phospholipids, which are responsible for 
its dynamic accumulation in regions of membrane-cytoskeleton connection3, 7, and in phosphatidyl inosi-
tol 4,5-bisphosphate-, cholesterol-, and glycosphingolipid-rich lipid rafts34, 35. Consistently, we show that 
LGRFYAASG-pen binds to intracellular annexin A2 at discontinuous membrane domains, potentially dis-
rupting its activity at these sites. In detail, we demonstrate that the intracellular annexin A2-targeting peptide 
LGRFYAASG-pen promotes disorganization of F-actin, disassembles focal adhesions, and reduces the number 
of lipid raft-associated trafficking vesicles.
Notably, the LGRFYAASG peptide sequence is a mimic of Cdc42, a member of the Rho family of GTPases 
(residues 53–60 of the human protein, UniProt entry P60953). This portion of Cdc42 is exposed when the protein 
is bound, e.g., to the serine/threonine-protein kinase PAK 1 (molecular modeling database, MMDB ID:12918) 
or Wiskott–Aldrich syndrome protein (WASP, MMDB ID:10496) during actin remodeling and filopodia forma-
tion37. The external location of this motif in the tertiary structure of Cdc42 suggests its physical accessibility as 
protein-protein recognition site. These observations are consistent with previous data indicating a direct interac-
tion between annexin A2 and Cdc42 in epithelial polarization, and de novo apical domain and lumen formation38, 
and thereby support the hypothesis that intracellular LGRFYAASG might act as a competitive inhibitor of the 
annexin A2/Cdc42 complex. Future research including X-ray crystallography studies might shed more light into 
this intriguing observation.
In addition to annexin A2, two other candidate proteins, CAPZA1 and LASP1, were enriched by affinity 
chromatography against LGRFYAASG-pen, but specific binding assays with LGRFYAASG-displaying iPhage 
particles demonstrated that they are not direct interactors of this peptide. Such proteins might bind the peptide 
indirectly, by taking part in a supramolecular complex that includes annexin A2. Consistently, our bioinfor-
matic analysis revealed that annexin A2, CAPZA1 and LASP1 indeed share common interactors. Among these, 
fibronectin 123, α-actin24, and Grb225, 26 are well-characterized in several signaling networks in cancer settings. 
Other interacting members, such as arrestin β2 (ARRB2)39, tumor necrosis factor (TNF) receptor associated fac-
tor 6 (TRAF6)40, prohibitin (PHB)3–5, 41, integrin α4 (ITGA4)42, and inversin (INVS)43 have been recently and/or 
marginally related to cancer cell motility and invasion. These data support the action of functional supramolec-
ular complexes, rather than a single protein species, in mediating adhesion and motility during cancer progres-
sion. As such, these integrated networks might be therapeutically targeted with potentially increased efficacy, for 
example by LGRFYAASG-pen, compared, e.g., to a classic small-molecule inhibitor targeting a single protein.
Figure 5. LGRFYAASG-pen inhibits the growth of experimental tumors in several preclinical models. 
Representative gross morphology of lungs explanted after 8 weeks (KRIB, (a), 21 days (B16F10, (b), 13 days 
(LLC, (c) after fixation in Bouin’s fixative, and corresponding lung weights (n = 8 animals/group) shown as 
mean ± SEM (****P < 0.0001, **P < 0.001, *P < 0.01 versus vehicle experimental points).
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In conclusion, here we show that a prototype peptide such as cell-internalizing LGRFYAASG-pen mechanisti-
cally interferes with intracellular annexin A2, representing a multifaceted inhibitor of cytoskeletal arrangements 
pivotal for key steps in cancer progression in preclinical tumor models. The potential for translation of these 
initial observations into clinical applications remains an open avenue for future studies.
Materials and Methods
Cells and reagents. KS1767, KRIB, B16F10 and LLC cells (ATCC) were maintained in Dulbecco’s modi-
fied Eagle’s Minimum Essential Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), vitamins, 
non-essential amino acids, penicillin/streptomycin, and L-glutamine (Gibco) at 37 °C in a 5% CO2 humidified 
incubator. The 4′,6-diamidino-2-phenylindole (DAPI) nuclear stain was from Vector Laboratories. Human 
recombinant annexin A1, annexin A2, annexin A4 and annexin A5 were from Amprox; fibronectin and vitronec-
tin were from R&D Systems; type I collagen I was from ScienCell Research Laboratories. Recombinant GST was 
produced in E. coli transformed with pGEX4T-1 plasmid (Amersham) and purified with standard protocols. All 
synthetic peptides were commercially manufactured and quality-controlled to our specifications (PolyPeptide 
Laboratories).
iPhage library intracellular selection. KS1767 cells were incubated with 5 × 1011 transducing units (TU) 
of the X4YX4 (X, any residue; Y, tyrosine) iPhage library overnight at 37 °C, extensively washed with pre-warmed 
PBS and subsequently detached with trypsin. Cell suspensions were washed with ice-cold PBS, incubated in 
hypotonic buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl pH 7.5) for 15 min, and disaggregated in a stand-
ard Dounce homogenizer. A stabilization buffer was added (final concentration: 84 mM mannitol, 70 nM sucrose, 
1 mM EDTA pH 7.5, 5 mM Tris-HCl pH 7.5), and the resulting organelle suspension was centrifuged at 1,300 g 
for 5 min at 4 °C to enrich for the nuclear fraction. The supernatant was recovered and centrifuged at 17,000 g for 
15 min; this pellet contained the mitochondrial/ER fraction. Finally, the remaining supernatant was centrifuged 
at 100,000 g for 40 min to obtain the cytosolic fraction. The cytosol-retained phage population was recovered, 
amplified and purified as described44. After five rounds of selection, 96 bacterial colonies from each fraction were 
randomly picked for DNA sequencing.
Affinity purification and identification of intracellular binding partners of LGRFYAASG. To 
isolate specific intracellular interactors, LGRFYAASG-pen was coupled to Sepharose columns (CarboxyLink 
Immobilization kit, Pierce) and incubated with KS1767 protein extracts. After extensive washing in phosphate 
buffered saline (PBS), bound proteins were eluted with the corresponding soluble peptide (5 mM). Eluted frac-
tions were analyzed by absorbance at 280 nm, dialyzed and concentrated at 4 °C. Total protein (5 µg/well in 50 µl 
PBS) was immobilized onto 96-well plates overnight at 4 °C. Wells were washed twice in PBS, blocked in PBS 
containing 2% BSA for 2 h at room temperature, and incubated with LGRFYAASG iPhage or insertless iPhage 
(109 TU) in 50 µl PBS with 0.1% BSA. After 2 h at room temperature, wells were washed ten times with PBS, and 
phage particles were recovered and quantified by bacterial infection. For the identification of bound proteins, 
the eluate from F46 was subjected to SDS-PAGE and specific bands were characterized with a Nano LC-MS/MS 
peptide sequencer (ProtTech) as described45.
Alanine-scanning mutagenesis of iPhage-displayed peptides. Mutant phage particles displaying 
alanine-scanning variants of LGRFYAASG were prepared by site-directed mutagenesis46. Briefly, the following 
oligonucleotide pairs (Sigma-Genosys) were annealed in 10 mM Tris-HCl pH 8.0, containing 100 mM NaCl, 
1 mM EDTA at 10 nM, and cloned into SfiI-digested fUSE5 vector with T4 DNA ligase (Roche):
AGRFYAASG -sense, 5′- GCGGGCCGCTTTTATGCGGCGAGCGGC-3′, and
AGRFYAASG -antisense, 5′-GCCGCTCGCCGCATAAAAGCGGCCCGC-3′;
LARFYAASG -sense, 5′-CTGGCGCGCTTTTATGCGGCGAGCGGC-3′, and
LARFYAASG -antisense, 5′-GCCGCTCGCCGCATAAAAGCGCGCCAG-3′
LGAFYAASG -sense, 5′-CTGGGCGCGTTTTATGCGGCGAGCGGC-3′, and
LGAFYAASG -antisense, 5′-GCCGCTCGCCGCATAAAACGCGCCCAG-3′;
LGRAYAASG -sense, 5′-CTGGGCCGCGCGTATGCGGCGAGCGGC-3′, and
LGRAYAASG -antisense, 5′-GCCGCTCGCCGCATACGCGCGGCCCAG-3′
LGRFAAASG -sense, 5′-CTGGGCCGCTTTGCGGCGGCGAGCGGC-3′, and
LGRFAAASG -antisense, 5′-GCCGCTCGCCGCCGCAAAGCGGCCCAG-3′;
LGRFYAAAG -sense, 5′-CTGGGCCGCTATGCGGCGGCGGGC-3′, and
LGRFYAAAG -antisense, 5′-GCCCGCCGCCGCATAGCGGCCCAG-3′;
LGRFYAASA -sense, 5′-CTGGGCCGCTTTTATGCGGCGAGCGCG-3′, and
LGRFYAASA -antisense, 5′-CGCGCTCGCCGCATAAAAGCGGCCCAG-3′.
iPhage binding assays were performed with an input of 109 TU/well in 96-well plates and bound phage parti-
cles were quantified by bacterial infection.
Confocal microscopy imaging. Cells were seeded onto circular coverslips in 24-well plates (1.5 × 105 cells/
coverslip) in complete medium and grown overnight at 37 °C in 5% CO2. For peptide/annexin A2 co-localization 
studies, adhered cells were pretreated with biotinylated pen, LGRFYAASG or LGRFYAASG-pen (10 µM in com-
plete medium) for 2 h at 37 °C. To evaluate F-actin organization, focal adhesions, and caveolae, the coverslips 
were pre-coated with either fibronectin/vitronectin or collagen I, and cell pretreatment with the indicated pep-
tides was extended overnight. In all cases, cells were then fixed in 4% paraformaldehyde in PBS for 10 min at 
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room temperature, followed by incubation in 50 mM ammonium chloride buffer for 30 min, blocking in PBS 
containing 1% BSA for 1 h, and permeabilization in 0.5% saponin, 0.1% BSA in Tris buffered saline (TBS) for 
30 min. The following primary antibodies were used: mouse monoclonal anti-annexin A2 1G7 (10 µg/ml) (Novus 
Biologicals), mouse monoclonal anti-paxillin (1:100) (BioLegend), rabbit polyclonal anti-caveolin 1 (1:200) 
(Abcam ab2910) for 16 h at 4 °C. Specific signals were revealed with the following secondary antibodies: goat 
anti-mouse-Cy3 (1:1,000) or Alexa 647 (1:200), goat anti-mouse-FITC (1:1,000), rabbit anti-mouse-FITC (1:1,000) 
(Jackson Immunoresearch Laboratories, West Grove, PA) for 1 h at room temperature. Biotin-conjugated peptides 
were visualized by incubation with avidin-FITC (5 µg/ml) (Invitrogen). For annexin A2/paxillin co-staining, cells 
were first incubated with the anti-annexin antibody overnight at 4 °C, followed by Alexa 647-conjugated goat 
anti-mouse secondary antibody for 1 h at room temperature; after extensive washing, cells were then incubated 
with the anti-paxillin antibody for 1 h at room temperature, followed by FITC-conjugated rabbit anti-mouse anti-
body for 1 h at room temperature. Actin was revealed by incubation with 5 units of rhodamine-phalloidin (Thermo 
Fisher Scientific) for 20 min at room temperature. Coverslips were mounted onto microscope slides in Vectashield 
(VectorLab) mounting media containing DAPI for nuclei staining. Images were acquired with a Leica TCS S8 con-
focal microscope (Leica Microsystems) and pixel co-localization was analyzed with Fiji ImageJ software47.
Western Blot. KS1767 cells were seeded (1 × 106) into 6 well plates and grown to 80% confluence. Cells 
were incubated with each peptide (100 µM) for 10, 30 and 60 min, followed by protein extraction in 50 mM 
Tris, 150 mM NaCl, 1% NP-40, phosphatase/protease inhibitors (Roche). Protein extracts were resolved by 
SDS-PAGE, transferred to nitrocellulose membranes and decorated with standard protocols. The following pri-
mary antibodies (all Cell Signaling) were used at a 1:1,000 dilution: rabbit polyclonal anti-Fak (#3285), rabbit 
monoclonal anti-phosphorylated Fak (Tyr397, #8556), mouse monoclonal anti-Akt (2H10), rabbit monoclonal 
anti-phosphorylated Akt (Ser473, D9E), rabbit monoclonal anti-phosphorylated p44/p42 (Thr202/Tyr204), and mouse 
monoclonal anti-Erk1/2 (p44/p42) (3A7). The rabbit anti-actin antibody (Sigma) was used at a 1:2,000 dilution.
Annexin A2 silencing. Silencing of annexin A2 expression was performed in KS1767 cells seeded into 6-well 
plates. Cell transduction was obtained with four alternative lentiviral shRNA clones directed against human 
annexin A2 (pGFP-C-shLenti, Origene Technologies). A scrambled shRNA lentivirus was used as a negative con-
trol. GFP-positive cells were sorted with a sy3200 Cell Sorter (Sony Biotechnology) and seeded into 6-well plates. 
Cell extracts were obtained in 50 mM Tris, 150 mM NaCl, 1% NP-40, phosphatase/protease inhibitors (Roche). 
To evaluate the downmodulation of annexin A2 protein, a Western blot was performed with a mouse monoclonal 
anti-annexin A2 (Novus Biologicals).
Cell adhesion, migration and viability/proliferation assays. For cell adhesion assays, 48-well 
flat-bottom plates were coated with 100 µl of fibronectin (20 µg/ml) or vitronectin (10 µg/ml) in PBS overnight at 
4 °C. Wells were washed twice with PBS and blocked with PBS containing 1% BSA for 2 h at room temperature. 
Suspended cells were preloaded with each peptide for 30 min at 37 °C, followed by incubation onto the coated 
wells (50,000 cells/well in 200 µl complete medium) at 37 °C for 1 h. Non-adherent cells were removed by exten-
sive washing with PBS. Adhered cells were counted under a light microscope (10 random fields/experimental 
point). For cell migration assays, 1 × 105 KS1767, KRIB or B16F10 cells were applied to the upper chamber of 
transwell inserts (Costar) in the presence of each peptide at 100 µM; LLC cells were incubated with 10 µM of the 
peptides. After 24 h, migrated cells were fixed, stained in crystal violet (Fisher) and counted (5 fields/well) under 
a light microscope. For the in vitro wound healing assays, cells were grown to confluence in 6-well plates, at which 
point a scratch (“wound”) was created with a pipetman tip. Cells were washed and incubated with either medium 
only, or each synthetic peptide at the indicated concentrations. Wounds were imaged under a phase contrast 
microscope at the beginning of the incubation and after 16 h, followed by scoring of the degree of closure. Cell 
viability/proliferation was evaluated by WST assay (Sigma Aldrich) in KS1767 cells grown in 48-well plates and 
maintained for 24, 48, 72 or 96 h in DMEM supplemented with 10% FBS plus each test peptide.
Tumor models. KRIB and B16F10 cells were incubated for 30 min with either pen, LGRFYAASG-pen, or 
LGRFYAASG at 100 µM, and LLC cells were incubated with the same peptides at 10 µM, followed by washing 
with non-supplemented DMEM. Cohorts of C57BL/6 females mice (n = 8), 8–12-weeks-old, were administered 
intravenously with 1 × 105 KRIB or B16F10 cells, or 1.5 × 105 LLC cells. After 8 weeks for KRIB cells, 21 days 
for B16F10 cells, and 13 days for LLC cells, lungs were removed, rinsed with PBS, and weighed. Lung lobes 
were dissociated and the number of tumor foci (dark color) was determined at both dorsal and ventral positions 
under a binocular dissection microscope for B16F10 cells. For KRIB and LLC cells, lungs were fixed in Bouin’s 
fixative (Sigma-Aldrich) overnight at room temperature. The following day, lungs were washed with 70% ethanol 
and tumor foci determined under a binocular dissection microscope. Five micron tissue sections were cut in a 
Microm HM 325 Rotary Microtome (Thermo Scientific, Walldorf, Germany) and stained with H&E, followed by 
image acquisition with a Nikon Ti-S Inverted Microscope (Nikon Instruments). The Institutional Animal Care 
and Use Committees (IACUCs) of both the University of Texas M. D. Anderson Cancer Center and the University 
of New Mexico health Sciences Center approved all animal experiments. All procedures reported in this paper 
were conducted in full compliance with the indications from the corresponding IACUCs, which follow the stand-
ard guide care and use of laboratory animals.
Bioinformatics and statistics. Ingenuity Pathway Analysis (IPA) software (Qiagen) was used to analyze 
protein-protein interactions with the canonical actin cytoskeletal signaling pathway. The assessment of statistical 
significance between groups was carried out according to one-way ANOVA test with the GraphPad Prism soft-
ware, the level of statistical significance defined as a value of P ≤ 0.05.
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